Back

Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: the PARACOR-19 randomized clinical trial

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - biomarkers 1 Biomarkers HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)

5 More presentations in this session

Presentation thumbnail
Rational use of natriuretic peptide testing in primary care - an observational study from a Danish regional hospital
Doctor L. Lylloff (Herning, DK) Associate Professor N. Hornung (Herning, DK)
Abstract Slides Video
Presentation thumbnail
Correlation of NT-proBNP and residual ischemic risk in patients with heart failure and myocardial revascularization.
Mrs J. Cazacu (Chisinau, MD)
Abstract Slides Video
Presentation thumbnail
CA125 assessment using ABEI-based assay in heart failure: implications for disease severity and cardiac biomarkers
Professor D. Gruson (Brussels, BE)
Abstract Slides Video
Presentation thumbnail
The relationship of natriuretic peptides and body mass index in chronic heart failure, a systematic review
Professor C. Ross (Belfast, GB)
Abstract Slides Video
Presentation thumbnail
QRS complex duration and type conduction disturbances as a simple predictor of left ventricle remodelation in patients with recent onset of dilated cardiomyopathy?
Professor R. Pudil (Prague, CZ)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - biomarkers 1

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Troponin elevation and vascular involvement post-COVID-19
thumbnail
Congress Presentation
Intensity of myocardial injury differs across SARS-CoV-2 variants in acute on chronic heart failure: a case study with matched control
thumbnail
Congress Presentation
Patients vaccinated against COVID-19 present better coronary flow, myocardial work and NTproNP levels than non-vaccinated at 4 months post COVID infection.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources